Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk.
Identifieur interne : 001185 ( Main/Exploration ); précédent : 001184; suivant : 001186Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk.
Auteurs : Louis Potier [France] ; Ronan Roussel [France] ; Yedid Elbez [France] ; Michel Marre [France] ; Uwe Zeymer [Allemagne] ; Christopher M. Reid [Australie] ; Magnus Ohman [États-Unis] ; Kim A. Eagle [États-Unis] ; Deepak L. Bhatt [États-Unis] ; Philippe Gabriel Steg [France]Source :
- Heart (British Cardiac Society) [ 1468-201X ] ; 2017.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Antagonistes des récepteurs aux angiotensines (usage thérapeutique), Enregistrements, Facteurs temps, Femelle, Humains, Incidence, Inhibiteurs de l'enzyme de conversion de l'angiotensine (usage thérapeutique), Maladies cardiovasculaires (), Maladies cardiovasculaires (épidémiologie), Morbidité (tendances), Mâle, Prévention secondaire (), Score de propension, Sujet âgé, Taux de survie (tendances), États-Unis d'Amérique (épidémiologie), Études de suivi, Études rétrospectives.
- MESH :
- tendances : Morbidité, Taux de survie.
- usage thérapeutique : Antagonistes des récepteurs aux angiotensines, Inhibiteurs de l'enzyme de conversion de l'angiotensine.
- épidémiologie : Maladies cardiovasculaires, États-Unis d'Amérique.
- Adulte d'âge moyen, Enregistrements, Facteurs temps, Femelle, Humains, Incidence, Maladies cardiovasculaires, Mâle, Prévention secondaire, Score de propension, Sujet âgé, Études de suivi, Études rétrospectives.
English descriptors
- KwdEn :
- Aged, Angiotensin Receptor Antagonists (therapeutic use), Angiotensin-Converting Enzyme Inhibitors (therapeutic use), Cardiovascular Diseases (epidemiology), Cardiovascular Diseases (prevention & control), Female, Follow-Up Studies, Humans, Incidence, Male, Middle Aged, Morbidity (trends), Propensity Score, Registries, Retrospective Studies, Secondary Prevention (methods), Survival Rate (trends), Time Factors, United States (epidemiology).
- MESH :
- chemical , therapeutic use : Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors.
- epidemiology : Cardiovascular Diseases, United States.
- methods : Secondary Prevention.
- prevention & control : Cardiovascular Diseases.
- trends : Morbidity, Survival Rate.
- Aged, Female, Follow-Up Studies, Humans, Incidence, Male, Middle Aged, Propensity Score, Registries, Retrospective Studies, Time Factors.
Abstract
ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are widely prescribed in patients with high cardiovascular (CV) risk. However, whether both classes have equivalent effectiveness to prevent CV events remains unclear. The aim of this study was to compare the incidence of major CV events between ACEI and ARB users.
DOI: 10.1136/heartjnl-2016-310705
PubMed: 28285267
Affiliations:
- Allemagne, Australie, France, États-Unis
- Caroline du Nord, Massachusetts, Michigan, Île-de-France
- Paris
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000662
- to stream PubMed, to step Curation: 000660
- to stream PubMed, to step Checkpoint: 000660
- to stream Ncbi, to step Merge: 004451
- to stream Ncbi, to step Curation: 004451
- to stream Ncbi, to step Checkpoint: 004451
- to stream Main, to step Merge: 001180
- to stream Main, to step Curation: 001185
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk.</title><author><name sortKey="Potier, Louis" sort="Potier, Louis" uniqKey="Potier L" first="Louis" last="Potier">Louis Potier</name><affiliation wicri:level="3"><nlm:affiliation>Département d'Endocrinologie, Diabétologie et Nutrition, DHU-FIRE, HUPNVS, AP-HP, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Département d'Endocrinologie, Diabétologie et Nutrition, DHU-FIRE, HUPNVS, AP-HP, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Roussel, Ronan" sort="Roussel, Ronan" uniqKey="Roussel R" first="Ronan" last="Roussel">Ronan Roussel</name><affiliation wicri:level="3"><nlm:affiliation>Département d'Endocrinologie, Diabétologie et Nutrition, DHU-FIRE, HUPNVS, AP-HP, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Département d'Endocrinologie, Diabétologie et Nutrition, DHU-FIRE, HUPNVS, AP-HP, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Elbez, Yedid" sort="Elbez, Yedid" uniqKey="Elbez Y" first="Yedid" last="Elbez">Yedid Elbez</name><affiliation wicri:level="3"><nlm:affiliation>FACT DHU FIRE, LVTS INSERM U-1148, Hôpital Bichat, HUPNVS, AP-HP, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>FACT DHU FIRE, LVTS INSERM U-1148, Hôpital Bichat, HUPNVS, AP-HP, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Marre, Michel" sort="Marre, Michel" uniqKey="Marre M" first="Michel" last="Marre">Michel Marre</name><affiliation wicri:level="3"><nlm:affiliation>Département d'Endocrinologie, Diabétologie et Nutrition, DHU-FIRE, HUPNVS, AP-HP, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Département d'Endocrinologie, Diabétologie et Nutrition, DHU-FIRE, HUPNVS, AP-HP, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Zeymer, Uwe" sort="Zeymer, Uwe" uniqKey="Zeymer U" first="Uwe" last="Zeymer">Uwe Zeymer</name><affiliation wicri:level="1"><nlm:affiliation>Klinikum Ludwigshafen und Institut für Herzinfarktforschung, Ludwigshafen, Rhineland-Palatinate, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Klinikum Ludwigshafen und Institut für Herzinfarktforschung, Ludwigshafen, Rhineland-Palatinate</wicri:regionArea><wicri:noRegion>Rhineland-Palatinate</wicri:noRegion><wicri:noRegion>Rhineland-Palatinate</wicri:noRegion><wicri:noRegion>Rhineland-Palatinate</wicri:noRegion></affiliation></author><author><name sortKey="Reid, Christopher M" sort="Reid, Christopher M" uniqKey="Reid C" first="Christopher M" last="Reid">Christopher M. Reid</name><affiliation wicri:level="1"><nlm:affiliation>Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, School of Public Health, Curtin University, Centre of Cardiovascular Research and Education in Therapeutics, Melbourne, Perth, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, School of Public Health, Curtin University, Centre of Cardiovascular Research and Education in Therapeutics, Melbourne, Perth</wicri:regionArea><wicri:noRegion>Perth</wicri:noRegion></affiliation></author><author><name sortKey="Ohman, Magnus" sort="Ohman, Magnus" uniqKey="Ohman M" first="Magnus" last="Ohman">Magnus Ohman</name><affiliation wicri:level="2"><nlm:affiliation>Division of Cardiology, Department of Medicine, Duke University Medical Center and the Duke Clinical Research Institute, Durham, North Carolina, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Cardiology, Department of Medicine, Duke University Medical Center and the Duke Clinical Research Institute, Durham, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Eagle, Kim A" sort="Eagle, Kim A" uniqKey="Eagle K" first="Kim A" last="Eagle">Kim A. Eagle</name><affiliation wicri:level="2"><nlm:affiliation>Department of Cardiology, University of Michigan Health System, Ann Arbor, Michigan, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Cardiology, University of Michigan Health System, Ann Arbor, Michigan</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Bhatt, Deepak L" sort="Bhatt, Deepak L" uniqKey="Bhatt D" first="Deepak L" last="Bhatt">Deepak L. Bhatt</name><affiliation wicri:level="2"><nlm:affiliation>Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, Massachusetts, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Steg, Philippe Gabriel" sort="Steg, Philippe Gabriel" uniqKey="Steg P" first="Philippe Gabriel" last="Steg">Philippe Gabriel Steg</name><affiliation wicri:level="3"><nlm:affiliation>Université Paris Diderot-Sorbonne Paris Cité, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université Paris Diderot-Sorbonne Paris Cité, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28285267</idno><idno type="pmid">28285267</idno><idno type="doi">10.1136/heartjnl-2016-310705</idno><idno type="wicri:Area/PubMed/Corpus">000662</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000662</idno><idno type="wicri:Area/PubMed/Curation">000660</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000660</idno><idno type="wicri:Area/PubMed/Checkpoint">000660</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000660</idno><idno type="wicri:Area/Ncbi/Merge">004451</idno><idno type="wicri:Area/Ncbi/Curation">004451</idno><idno type="wicri:Area/Ncbi/Checkpoint">004451</idno><idno type="wicri:Area/Main/Merge">001180</idno><idno type="wicri:Area/Main/Curation">001185</idno><idno type="wicri:Area/Main/Exploration">001185</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk.</title><author><name sortKey="Potier, Louis" sort="Potier, Louis" uniqKey="Potier L" first="Louis" last="Potier">Louis Potier</name><affiliation wicri:level="3"><nlm:affiliation>Département d'Endocrinologie, Diabétologie et Nutrition, DHU-FIRE, HUPNVS, AP-HP, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Département d'Endocrinologie, Diabétologie et Nutrition, DHU-FIRE, HUPNVS, AP-HP, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Roussel, Ronan" sort="Roussel, Ronan" uniqKey="Roussel R" first="Ronan" last="Roussel">Ronan Roussel</name><affiliation wicri:level="3"><nlm:affiliation>Département d'Endocrinologie, Diabétologie et Nutrition, DHU-FIRE, HUPNVS, AP-HP, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Département d'Endocrinologie, Diabétologie et Nutrition, DHU-FIRE, HUPNVS, AP-HP, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Elbez, Yedid" sort="Elbez, Yedid" uniqKey="Elbez Y" first="Yedid" last="Elbez">Yedid Elbez</name><affiliation wicri:level="3"><nlm:affiliation>FACT DHU FIRE, LVTS INSERM U-1148, Hôpital Bichat, HUPNVS, AP-HP, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>FACT DHU FIRE, LVTS INSERM U-1148, Hôpital Bichat, HUPNVS, AP-HP, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Marre, Michel" sort="Marre, Michel" uniqKey="Marre M" first="Michel" last="Marre">Michel Marre</name><affiliation wicri:level="3"><nlm:affiliation>Département d'Endocrinologie, Diabétologie et Nutrition, DHU-FIRE, HUPNVS, AP-HP, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Département d'Endocrinologie, Diabétologie et Nutrition, DHU-FIRE, HUPNVS, AP-HP, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Zeymer, Uwe" sort="Zeymer, Uwe" uniqKey="Zeymer U" first="Uwe" last="Zeymer">Uwe Zeymer</name><affiliation wicri:level="1"><nlm:affiliation>Klinikum Ludwigshafen und Institut für Herzinfarktforschung, Ludwigshafen, Rhineland-Palatinate, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Klinikum Ludwigshafen und Institut für Herzinfarktforschung, Ludwigshafen, Rhineland-Palatinate</wicri:regionArea><wicri:noRegion>Rhineland-Palatinate</wicri:noRegion><wicri:noRegion>Rhineland-Palatinate</wicri:noRegion><wicri:noRegion>Rhineland-Palatinate</wicri:noRegion></affiliation></author><author><name sortKey="Reid, Christopher M" sort="Reid, Christopher M" uniqKey="Reid C" first="Christopher M" last="Reid">Christopher M. Reid</name><affiliation wicri:level="1"><nlm:affiliation>Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, School of Public Health, Curtin University, Centre of Cardiovascular Research and Education in Therapeutics, Melbourne, Perth, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, School of Public Health, Curtin University, Centre of Cardiovascular Research and Education in Therapeutics, Melbourne, Perth</wicri:regionArea><wicri:noRegion>Perth</wicri:noRegion></affiliation></author><author><name sortKey="Ohman, Magnus" sort="Ohman, Magnus" uniqKey="Ohman M" first="Magnus" last="Ohman">Magnus Ohman</name><affiliation wicri:level="2"><nlm:affiliation>Division of Cardiology, Department of Medicine, Duke University Medical Center and the Duke Clinical Research Institute, Durham, North Carolina, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Cardiology, Department of Medicine, Duke University Medical Center and the Duke Clinical Research Institute, Durham, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Eagle, Kim A" sort="Eagle, Kim A" uniqKey="Eagle K" first="Kim A" last="Eagle">Kim A. Eagle</name><affiliation wicri:level="2"><nlm:affiliation>Department of Cardiology, University of Michigan Health System, Ann Arbor, Michigan, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Cardiology, University of Michigan Health System, Ann Arbor, Michigan</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Bhatt, Deepak L" sort="Bhatt, Deepak L" uniqKey="Bhatt D" first="Deepak L" last="Bhatt">Deepak L. Bhatt</name><affiliation wicri:level="2"><nlm:affiliation>Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, Massachusetts, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Steg, Philippe Gabriel" sort="Steg, Philippe Gabriel" uniqKey="Steg P" first="Philippe Gabriel" last="Steg">Philippe Gabriel Steg</name><affiliation wicri:level="3"><nlm:affiliation>Université Paris Diderot-Sorbonne Paris Cité, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université Paris Diderot-Sorbonne Paris Cité, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></analytic><series><title level="j">Heart (British Cardiac Society)</title><idno type="eISSN">1468-201X</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Angiotensin Receptor Antagonists (therapeutic use)</term><term>Angiotensin-Converting Enzyme Inhibitors (therapeutic use)</term><term>Cardiovascular Diseases (epidemiology)</term><term>Cardiovascular Diseases (prevention & control)</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Incidence</term><term>Male</term><term>Middle Aged</term><term>Morbidity (trends)</term><term>Propensity Score</term><term>Registries</term><term>Retrospective Studies</term><term>Secondary Prevention (methods)</term><term>Survival Rate (trends)</term><term>Time Factors</term><term>United States (epidemiology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Antagonistes des récepteurs aux angiotensines (usage thérapeutique)</term><term>Enregistrements</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Incidence</term><term>Inhibiteurs de l'enzyme de conversion de l'angiotensine (usage thérapeutique)</term><term>Maladies cardiovasculaires ()</term><term>Maladies cardiovasculaires (épidémiologie)</term><term>Morbidité (tendances)</term><term>Mâle</term><term>Prévention secondaire ()</term><term>Score de propension</term><term>Sujet âgé</term><term>Taux de survie (tendances)</term><term>États-Unis d'Amérique (épidémiologie)</term><term>Études de suivi</term><term>Études rétrospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Angiotensin Receptor Antagonists</term><term>Angiotensin-Converting Enzyme Inhibitors</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Cardiovascular Diseases</term><term>United States</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Secondary Prevention</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Cardiovascular Diseases</term></keywords><keywords scheme="MESH" qualifier="tendances" xml:lang="fr"><term>Morbidité</term><term>Taux de survie</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Morbidity</term><term>Survival Rate</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antagonistes des récepteurs aux angiotensines</term><term>Inhibiteurs de l'enzyme de conversion de l'angiotensine</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Maladies cardiovasculaires</term><term>États-Unis d'Amérique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Incidence</term><term>Male</term><term>Middle Aged</term><term>Propensity Score</term><term>Registries</term><term>Retrospective Studies</term><term>Time Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Enregistrements</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Incidence</term><term>Maladies cardiovasculaires</term><term>Mâle</term><term>Prévention secondaire</term><term>Score de propension</term><term>Sujet âgé</term><term>Études de suivi</term><term>Études rétrospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are widely prescribed in patients with high cardiovascular (CV) risk. However, whether both classes have equivalent effectiveness to prevent CV events remains unclear. The aim of this study was to compare the incidence of major CV events between ACEI and ARB users.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>France</li><li>États-Unis</li></country><region><li>Caroline du Nord</li><li>Massachusetts</li><li>Michigan</li><li>Île-de-France</li></region><settlement><li>Paris</li></settlement></list><tree><country name="France"><region name="Île-de-France"><name sortKey="Potier, Louis" sort="Potier, Louis" uniqKey="Potier L" first="Louis" last="Potier">Louis Potier</name></region><name sortKey="Elbez, Yedid" sort="Elbez, Yedid" uniqKey="Elbez Y" first="Yedid" last="Elbez">Yedid Elbez</name><name sortKey="Marre, Michel" sort="Marre, Michel" uniqKey="Marre M" first="Michel" last="Marre">Michel Marre</name><name sortKey="Roussel, Ronan" sort="Roussel, Ronan" uniqKey="Roussel R" first="Ronan" last="Roussel">Ronan Roussel</name><name sortKey="Steg, Philippe Gabriel" sort="Steg, Philippe Gabriel" uniqKey="Steg P" first="Philippe Gabriel" last="Steg">Philippe Gabriel Steg</name></country><country name="Allemagne"><noRegion><name sortKey="Zeymer, Uwe" sort="Zeymer, Uwe" uniqKey="Zeymer U" first="Uwe" last="Zeymer">Uwe Zeymer</name></noRegion></country><country name="Australie"><noRegion><name sortKey="Reid, Christopher M" sort="Reid, Christopher M" uniqKey="Reid C" first="Christopher M" last="Reid">Christopher M. Reid</name></noRegion></country><country name="États-Unis"><region name="Caroline du Nord"><name sortKey="Ohman, Magnus" sort="Ohman, Magnus" uniqKey="Ohman M" first="Magnus" last="Ohman">Magnus Ohman</name></region><name sortKey="Bhatt, Deepak L" sort="Bhatt, Deepak L" uniqKey="Bhatt D" first="Deepak L" last="Bhatt">Deepak L. Bhatt</name><name sortKey="Eagle, Kim A" sort="Eagle, Kim A" uniqKey="Eagle K" first="Kim A" last="Eagle">Kim A. Eagle</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001185 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001185 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28285267
|texte= Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28285267" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |